Development of nanoparticulate systems with action in breast and ovarian cancer: nanotheragnostics

Cunha, Fabiana de Sousa; Pereira, Luciana Patrícia Lima Alves; Silva, Thâmara Pryscilla de Costa E; Luz, Roberto A. S.; Mendes, Anderson Nogueira

doi:10.1080/1061186x.2018.1523418

Cited by 17 publications

(7 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer and ovarian cancer are the most frequently occurred gynecological cancers globally, severely threatened the life quality of females ( de Sousa Cunha et al, 2019 ; Siegel et al, 2020 ). Breast cancer has gain great attentions caused by its constantly increasing incidence despite of the improvement in treatment ( Britt et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Lidocaine Promoted Ferroptosis by Targeting miR-382-5p /SLC7A11 Axis in Ovarian and Breast Cancer

Sun

Zhang

2021

Front. Pharmacol.

View full text Add to dashboard Cite

Ovarian and breast cancer are prevalent female malignancies with increasing occurrence incidence and metastasis, significantly affecting the health and life quality of women globally. Anesthetic lidocaine has presented anti-tumor activities in the experimental conditions. However, the effect of lidocaine on ovarian and breast cancer remains elusive. We identified the important function of lidocaine in enhancing ferroptosis and repressing progression of ovarian and breast cancer. Our data showed that lidocaine further repressed erastin-inhibited ovarian and breast cancer cell viabilities. The treatment of lidocaine induced accumulation of Fe2+, iron and lipid reactive oxygen species (ROS) in ovarian and breast cancer cells. The ovarian and breast cancer cell proliferation was suppressed while cell apoptosis was induced by lidocaine in vitro. Lidocaine attenuated invasion and migration of ovarian and breast cancer cells as well. Regarding the mechanism, we found that lidocaine downregulated solute carrier family 7 member 11 (SLC7A11) expression by enhancing microRNA-382-5p (miR-382-5p) in the cells. The inhibition of miR-382-5p blocked lidocaine-induced ferroptosis of ovarian and breast cancer cells. MiR-382-5p/SLC7A11 axis was involved in lidocaine-mediated inhibition of ovarian and breast cancer cell proliferation in vitro. The miR-382-5p expression was down-regulated but SLC7A11 expression was up-regulated in clinical ovarian and breast cancer samples. Furthermore, the treatment of lidocaine repressed tumor growth of ovarian cancer cells in vivo, in which the miR-382-5p expression was increased while SLC7A11 expression was decreased. Consequently, we concluded that the lidocaine promoted ferroptosis by miR-382-5p/SLC7A11 axis in ovarian and breast cancer cells. The clinical value of lidocaine in the treatment of ovarian and breast cancer deserves to be proved in detail.

show abstract

Section: Introductionmentioning

confidence: 99%

Lidocaine Promoted Ferroptosis by Targeting miR-382-5p /SLC7A11 Axis in Ovarian and Breast Cancer

Sun

Zhang

2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Despite the growing body of scientific evidence on the use of IONPs in drug delivery systems, not all relevant drugs of medical/dental interest have been investigated, either alone or in combination with IONPs [123]. In this sense, the conception of novel IONPs-based nano systems able to carry multiple drugs simultaneously and with adequate release control on the target tissues could be beneficial in several clinical situations [123,124]. These include the prevention/control of diseases associated with multiple microorganisms (e.g., bacteria and fungi), as well as conditions that require different categories of drugs (e.g., anti-inflammatory, antibiotics, and antifungal).…”

Section: Discussionmentioning

confidence: 99%

Iron oxide nanoparticles approaching to eradicate her2-positive breast cancer

Kumar

Sagar³

et al. 2022

ijhs

View full text Add to dashboard Cite

Background: Breast cancer is the second foremostreason for death in femalesuniversal. The enormously fast level of metastasis and capability to growconfrontationmethods to all the unoriginalmedications make them self-sameproblematic to indulgence which the reasons for in elevation morbidity and mortality are of breast melanoma patients. Expertsall through the world have been directing on the firstdiscovery of breast lump so that conduct can be started at the very primary stage. Furthermore, conventional treatment methods such as chemotherapy, radiotherapy, and local surgical treatmentsmart from innumerablerestrictions including toxicity, genetic mutation of normal cells, and spreading of cancer cells to healthy tissues. Therefore, new treatment schedules with low toxicity to usual cells need to be immediatelyadvanced. Methods: Iron oxide nanoparticles have remainedextensively used for targeting hyperthermia and imaging of breast growth cells. They can be conjugated with drugs, proteins, enzymes, antibodies, or nucleotides to bring them to target organs, tissues, or tumors using an external magnetic field. Results: Iron oxide nanoparticles have remainedpositively used as theranosticscauses for breast malignancy both in vitro and in vivo. Besides, their functions with medications or functional biomolecules increase their drug delivery efficiency and decrease the systemic noxiousness of drugs.

show abstract

“…The micelles were conjugated with iNGR peptide to target NRP-1 receptor in TNBC. These PTX micelles showed higher uptake in TNBC than the non-targeted micelles and Taxol ® (22). Another study on PTX bounded albumin liposome (Abraxane ® ), revealed to be an effective nano-carrier to deliver the drug in TNBC.…”

Section: Passive Targetingmentioning

confidence: 96%

Potent Nano Carriers for Targeting Breast Cancer

Sangam¹,

Shekar²

2020

IJAR

View full text Add to dashboard Cite

Breast cancer (BC) is the most common cancer in female population. Triple-negative breast cancer (TNBC) is the subtype of breast cancer in which the three major receptors are absent. TNBC has very aggressive phenotype and high spreading rate/metastasis which often results in resistance to chemotherapy. Nano-medicines offer various promising approaches to BC and TNBC therapy because of its unique characteristics viz.nanometric size, high drug payload, targeting capabilities and capability to accommodate multiple therapeutic moieties.This review focuses on the conventional therapies, novel approaches and recent treatment strategies available for the therapeutic benefits to the patients. The role of cancer stem cell in the recurrence of BC and TNBC has also been highlighted. Moreover, the application of nanomedicines for the treatment of BC/TNBC and different molecular targets available for further exploration have also been discussed.Nanomedicines offers a right platform to develop multifaceted treatment strategies to control the spread and recurrence of BC/TNBC. Researchers explored multiple pathways that can play a major role in controlling the progression of TNBC. Several chemotherapeutic agents were delivered using these nanocarriers with outstanding responses. Numerous targets were also reported that could stop/alter the specific pathway or receptor interaction.

show abstract

Development of nanoparticulate systems with action in breast and ovarian cancer: nanotheragnostics

Cited by 17 publications

References 107 publications

Lidocaine Promoted Ferroptosis by Targeting miR-382-5p /SLC7A11 Axis in Ovarian and Breast Cancer

Lidocaine Promoted Ferroptosis by Targeting miR-382-5p /SLC7A11 Axis in Ovarian and Breast Cancer

Iron oxide nanoparticles approaching to eradicate her2-positive breast cancer

Potent Nano Carriers for Targeting Breast Cancer

Contact Info

Product

Resources

About